Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Eluminex Biosciences Exclusively Licenses FibroGen’s Biosynthetic Cornea Technology And Recombinant Collagen III Platform; Co. To Pay FibroGen $8M Up Front And Up To $64M In Milestones As Well As $46M In Commercial Milestones

Exclusive Global Development and Commercialization Rights for Recombinant Human Collagen-Based Biosynthetic Cornea Clinical Stage Asset Has Potential for First Approved Biosynthetic Human Cornea Biosynthetic

FGEN

Read More

The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs

Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears, and exerted negative pressure on stocks. There were very few stock-specific catalysts, barring a few preannouncements, stock offerings, and a slew of initial public offerings.

ABT